Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment
SPC-15 combination treatment shows enhanced efficacy in combating stress-induced psychiatric disorders
SARASOTA, FL, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a provisional patent application with the U.S. Patent and Trademark Office (USPTO) for its lead asset SPC-15.
Silo currently has patents issued and numerous expanded patent applications pending for SPC-15, a technology that was originally licensed through a collaboration with Columbia University.
The provisional patent covers a dual-action method and composition for combating stress-induced pathophysiology and reducing a variety of stress-induced psychiatric behaviors. A of SPC-15, a serotonin type IV receptor (5-HT4R) agonist, combined with an N-methyl-D-aspartate receptor (NMDAR) antagonist demonstrated significant improvement in behavioral outcomes and a marked reduction in severe stress-induced conditions.
“We believe that the SPC-15 combination treatment is showing promise in multiple stress-induced behaviors and disorders. This provisional patent application, if approved and the patent issued, will augment and expand the existing patents on this technology which we originally acquired through our global license agreement,” said Eric Weisblum, CEO of Silo.
Silo recently filed a separate expanded provisional patent application covering the chronic, combinatorial targeting of NMDARs and 5-HT4Rs to extend behavioral effects against stress-induced perseverative behavior and hyponeophagia.
About SPC-15
SPC-15 is an intranasal serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders such as PTSD and anxiety. With its potential eligibility for the FDA’s streamlined 505(b)(2) regulatory pathway, SPC-15 offers a promising approach to accelerate the approval process. Silo Pharma is collaborating with Columbia University to conduct preclinical studies and has exclusive global rights to the development and commercialization of SPC-15.
About Silo Pharma
Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company focused on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories.
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.
Contact
800-705-0120
